Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Line Treatment ◽

Second Line ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

First Line Therapy ◽

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.4077 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 4077-4077 ◽

Cited By ~ 1

Author(s):

Ian Chau ◽

Markus Peck-Radosavljevic ◽

Christophe Borg ◽

Peter Malfertheiner ◽

Jean Francois Seitz ◽

...

Keyword(s):

Line Treatment ◽

Second Line ◽

First Line ◽

Phase 3 ◽

First Line Therapy ◽

Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25]

European Journal of Cancer ◽

10.1016/j.ejca.2018.06.002 ◽

2018 ◽

Vol 100 ◽

pp. 135-136

Author(s):

Ian Chau ◽

Markus Peck-Radosavljevic ◽

Christophe Borg ◽

Peter Malfertheiner ◽

Jean Francois Seitz ◽

...

Keyword(s):

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

First Line Therapy ◽

Hepatic reserve and the other conditions for regorafenib as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib in Japanese practical setting

Annals of Oncology ◽

10.1093/annonc/mdx660.047 ◽

2017 ◽

Vol 28 ◽

pp. x71

Author(s):

T. Terashima ◽

T. Yamashita ◽

K. Arai ◽

S. Kaneko

Keyword(s):

The Other ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Hepatic Reserve ◽

First Line Therapy ◽

REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.4003 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 4003-4003 ◽

Cited By ~ 41

Author(s):

Andrew X. Zhu ◽

Yoon-Koo Kang ◽

Chia-Jui Yen ◽

Richard S. Finn ◽

Peter R. Galle ◽

...

Keyword(s):

Alpha Fetoprotein ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

O-005 Ramucirumab (RAM) as second-Line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: comprehensive results from the randomized phase III REACH study

Annals of Oncology ◽

10.1093/annonc/mdv235.04 ◽

2015 ◽

Vol 26 ◽

pp. iv109

Author(s):

A. Zhu ◽

M. Kudo ◽

J.O. Park ◽

B.-Y. Ryoo ◽

C.-J. Yen ◽

...

Keyword(s):

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

First Line Therapy ◽

Ramucirumab (RAM) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) Following First-Line Therapy with Sorafenib: Analyses from the Randomized Phase III REACH Study

Annals of Oncology ◽

10.1093/annonc/mdv344.03 ◽

2015 ◽

Vol 26 ◽

pp. vi90 ◽

Cited By ~ 1

Author(s):

C. Barone ◽

G. Brandi ◽

B. Daniele ◽

E. Villa ◽

S. Leo ◽

...

Keyword(s):

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

First Line Therapy ◽

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70127-0 ◽

2015 ◽

Vol 16 (5) ◽

pp. 499-508 ◽

Cited By ~ 406

Author(s):

Josep Tabernero ◽

Takayuki Yoshino ◽

Allen Lee Cohn ◽

Radka Obermannova ◽

Gyorgy Bodoky ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Second Line ◽

Metastatic Colorectal Carcinoma ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

First Line Therapy ◽

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study

European Journal of Cancer ◽

10.1016/j.ejca.2017.05.001 ◽

2017 ◽

Vol 81 ◽

pp. 17-25 ◽

Cited By ~ 22

Author(s):

Ian Chau ◽

Markus Peck-Radosavljevic ◽

Christophe Borg ◽

Peter Malfertheiner ◽

Jean Francois Seitz ◽

...

Keyword(s):

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

First Line Therapy ◽

2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment

European Journal of Cancer ◽

10.1016/s0959-8049(16)31253-9 ◽

2015 ◽

Vol 51 ◽

pp. S446

Author(s):

I. Chau ◽

J.O. Park ◽

B.Y. Ryoo ◽

C.J. Yen ◽

R. Poon ◽

...

Keyword(s):

Alpha Fetoprotein ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Study Analysis ◽

First Line ◽

First Line Therapy ◽

Ramucirumab (Ram) As Second-Line Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III Reach Study

Annals of Oncology ◽

10.1093/annonc/mdu438.16 ◽

2014 ◽

Vol 25 ◽

pp. v1 ◽

Cited By ~ 13

Author(s):

A.X. Zhu ◽

B.Y. Ryoo ◽

C.J. Yen ◽

M. Kudo ◽

R. Poon ◽

...

Keyword(s):

Phase Iii ◽

Line Treatment ◽

Second Line ◽

First Line ◽

First Line Therapy ◽